Ibutamoren

Research

Ibutamoren (MK-677)

Category
Growth Hormone
Aliases
MK-677, Nutrobal
Administration
Oral

Research and regulatory

Development stage

Phase II/III trials for growth hormone deficiency and age-related frailty; development discontinued by originator after failing to show functional benefit despite raising IGF-1.

Legal and regulatory

Unscheduled research compound; not FDA approved. Prohibited by WADA for competitive athletes.

Side effects

Increased appetite, water retention, elevated blood sugar, potential insulin resistance with long-term use